Parker’s 2D DuraPure™ C93 bioprocess containers will now be manufactured at the company’s site in Birtley, North East England, complementing existing production at its facility in Oxnard, California and strengthening Parker’s service provision to its European customers.
DuraPure™ C93 film is a high clarity medical film designed to provide an effective combination of strength, flexibility, gas barrier and low extractables. The 2D The DuraPure™ C93 container systems have a wide range of uses across bioprocessing, including buffer preparation, the storage of purified antibodies and fluid transfer.
The DuraPure™ C93 single-use container systems will be manufactured and validated at an ISO Class 7 clean room at Parker’s Birtley premises, which was opened in 2016. Their manufacture will complement the production of single-use manifolds, which commenced last year following the opening of the clean room, and has been enabled by increased investment in manufacturing equipment at the Birtley facility.
Parker – which designs, supplies and delivers whole systems for both upstream and downstream pharmaceutical and biopharmaceutical manufacturing – also recently announced that it had commenced the manufacture a wide range of automated systems to European standards at its Birtley site. These include the SciLog® Filter and Dispense System, designed for bulk drug filter and dispense, the SciLog® SciPure System, a GMP-ready system for tangential flow or normal flow filtration applications, and the SciLog® SciFlex TFF System, which is used for tangential flow filtration applications, from discovery to production.
The manufacture of DuraPure™ C93 single-use container systems in Birtley – along with single-use manifolds and automated systems – further demonstrates Parker’s commitment to supporting biopharmaceutical companies in European markets, and will enable customers to have greater and more rapid access to specialist products and associated technical support.
In addition, by manufacturing products and systems from dual sites in the UK and USA, additional assurance is provided for customers.
Graeme Proctor, product manager (Life Sciences) at Parker said: “Our DuraPure™ C93 single-use container systems designed are to seamlessly integrate into a process, from media prep to cell culture or ultrafiltration to final fill, and their multiple capabilities have proved extremely useful to customers across the globe.
“We are committed to supporting the European biopharmaceutical sector and the provision of DuraPure™ C93 single-use container systems at our Birtley site will shorten the supply chain for Europe-based companies, enabling them to be more responsive to market demands and cut down on lead times.
“Coupled with the provision of single-use manifolds and automated systems from the UK as well the USA, this enhanced capability will help us to provide solutions to biopharmaceutical firms more quickly and efficiently, and increase confidence in the integrity and robustness of their own operations.”
For more information, visit www.parker.com/bioprocessing
About Parker in Bioprocessing
Parker provides integrated bioprocessing solutions that speed up development times, increase efficiency and safety, and enable reproducible quality. Incorporating SciLog®, Parker domnick hunter combines filtration, single-use fluid-handling systems and sensors into automated single-use solutions. Visit www.parker.com/bioprocessing to learn how we can create your single-use solution.
About Parker Hannifin Corporation
With annual sales of $11 billion in fiscal year 2016, Parker Hannifin is the world's leading diversified manufacturer of motion and control technologies and systems, providing precision-engineered solutions for a wide variety of mobile, industrial and aerospace markets. The company has operations in 49 countries around the world. Parker has increased its annual dividends paid to shareholders for 60 consecutive fiscal years, among the top five longest-running dividend-increase records in the S&P 500 index. For more information, visit the company's website at www.parker.com, or its investor information website at www.phstock.com.
SOURCE: Parker Hannifin Corporation